MK-0616: Clinical Trials

8 trials of MK-0616, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 active not recruiting, 2 recruiting. 8 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 38Completed 4, Active not recruiting 2, Recruiting 2
Phase 21Recruiting 1

Follow MK-0616: new trials by email Literature Review of MK-0616 trials Research Report on MK-0616

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)
Enlicitide Decanoate, Placebo - Hyperlipidemia, Hypercholesterolemia
Phase 3RecruitingMerck Sharp & Dohme LLC1502026-10-152026-11-02
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Enlicitide, Rosuvastatin, Placebo for Enlicitide - Hyperlipidemia
Phase 3CompletedMerck Sharp & Dohme LLC9962025-11-112026-11-17
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Enlicitide Decanoate, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 2 / Phase 3RecruitingMerck Sharp & Dohme LLC1532025-08-212026-11-12
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
Enlicitide Decanoate - Hypercholesterolemia
Phase 3Active not recruitingMerck Sharp & Dohme LLC30002024-08-052025-10-07
A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
Enlicitide, Ezetimibe, Bempedoic Acid - Hypercholesterolemia
Phase 3CompletedMerck Sharp & Dohme LLC3012024-07-082026-03-27
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
Enlicitide Decanoate, Placebo - Arteriosclerosis, Hypercholesterolaemia
Phase 3Active not recruitingMerck Sharp & Dohme LLC145502023-10-092026-04-23
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
Enlicitide Decanoate, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia
Phase 3CompletedMerck Sharp & Dohme LLC29122023-08-102026-09-24
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
Enlicitide Decanoate, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia
Phase 3CompletedMerck Sharp & Dohme LLC3032023-08-082026-02-24

Conditions studied

Hypercholesterolemia (6)  ·  Hyperlipidemias (2)  ·  Hyperlipoproteinemia Type II (2)  ·  Arteriosclerosis (1)

Sponsors

Merck Sharp & Dohme LLC (8)

Countries

Spain (7)  ·  United States (7)  ·  Israel (6)  ·  Argentina (5)  ·  Australia (5)  ·  Brazil (5)  ·  Canada (5)  ·  Colombia (5)  ·  New Zealand (5)  ·  Taiwan (5)  ·  United Kingdom (5)  ·  Chile (4)  ·  China (4)  ·  France (4)  ·  Germany (4)

Results publications

PMID 41206969, PMID 41879224, PMID 42017875

NIH funding

2023 (2)